Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In SelectQuote (SLQT) To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in SelectQuote between September 9, 2020 and May 1, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648. Click here to participate in the action. NEW YORK, Oct. 10, 2025 (GLOBE NEWSWIRE) -- What’s Happen ...

Core Viewpoint - A class action lawsuit has been filed against Semler Scientific, Inc. for allegedly making materially false and misleading statements regarding a Department of Justice investigation into violations of the False Claims Act, which has led to investor losses during the class period from March 10, 2021, to April 15, 2025 [3][7]. Allegation Details - The lawsuit claims that Semler Scientific failed to disclose a significant investigation by the DOJ into potential violations of the False Claims Act while discussing such violations in hypothetical terms [3]. - As a result of these omissions, the public statements made by the defendants were materially false and misleading throughout the relevant period [3]. Next Steps for Investors - Investors who purchased or acquired Semler shares and suffered losses are encouraged to contact the law firm Bragar Eagel & Squire for more information regarding their rights and potential claims [4][7]. - The deadline for investors to apply to be appointed as lead plaintiff in the lawsuit is October 28th [7]. About the Law Firm - Bragar Eagel & Squire, P.C. is a nationally recognized law firm that represents individual and institutional investors in complex litigation across various courts in the United States [5].

Core Viewpoint - A class action lawsuit has been filed against SelectQuote, Inc. for allegedly receiving illegal kickbacks from health insurance companies and misleading investors about its business practices [6]. Allegation Details - The U.S. Department of Justice filed a complaint against SelectQuote, alleging that from 2016 to at least 2021, the company received "tens of millions of dollars" in illegal kickbacks for steering Medicare beneficiaries to specific insurance plans [6]. - The lawsuit claims that SelectQuote made materially false statements and failed to disclose adverse facts about its operations, including directing beneficiaries to plans that compensated the company the most, rather than providing unbiased comparisons [6]. Stock Impact - Following the DOJ's announcement, SelectQuote's stock price dropped by $0.61, or 19.2%, closing at $2.56 per share on May 1, 2025, with unusually high trading volume [6]. Legal Process - Investors who purchased SelectQuote securities between September 9, 2020, and May 1, 2025, have until October 10, 2025, to apply to be appointed as lead plaintiff in the lawsuit [6].

Core Viewpoint - A class action lawsuit has been filed against Semler Scientific, Inc. for failing to disclose a material investigation by the U.S. Department of Justice regarding potential violations of the False Claims Act [2][3]. Group 1: Allegations and Investigations - Semler Scientific is accused of not disclosing an investigation by the DOJ into possible violations of the False Claims Act during the class period from March 10, 2021, to April 15, 2025 [2]. - The company received an initial civil investigative demand (CID) from the DOJ in July 2017, which investigated whether it violated the False Claims Act by marketing certain tests as reimbursable by Medicare [3]. - On February 11, 2025, Semler Scientific engaged in unsuccessful settlement discussions with the DOJ, raising concerns about a potential lawsuit [3]. Group 2: Financial Impact - Following the revelation of the investigation on February 28, 2025, Semler Scientific's stock price dropped by $4.03, or 9.38%, closing at $38.89 on March 3, 2025 [3]. - After the company announced a settlement agreement with the DOJ for $29.75 million on April 15, 2025, the stock fell by $3.40, or 9.88%, to close at $31.00 on April 16, 2025 [4]. Group 3: Class Action Participation - Shareholders interested in participating in the class action must submit their paperwork by October 28, 2025, to serve as lead plaintiff [5]. - Shareholders do not need to participate in the case to be eligible for recovery, and they can remain absent class members if they choose [5].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Semler Scientific, Inc. securities during the specified class period of the upcoming lead plaintiff deadline for a securities class action lawsuit [1][3]. Group 1: Class Action Details - The class period for the Semler Scientific securities is from March 10, 2021, to April 15, 2025 [1]. - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the court to serve as lead plaintiff by October 28, 2025 [3]. Group 2: Legal Representation - Investors are encouraged to select qualified legal counsel with a proven track record in securities class actions [4]. - Rosen Law Firm has a history of significant settlements, including the largest securities class action settlement against a Chinese company at the time [4]. - The firm has consistently ranked highly in securities class action settlements and has recovered hundreds of millions of dollars for investors [4]. Group 3: Case Allegations - The lawsuit alleges that Semler Scientific made materially false and misleading statements and failed to disclose a significant investigation by the U.S. Department of Justice regarding violations of the False Claims Act [5]. - The lawsuit claims that these misstatements led to investor damages when the true details became public [5].

Core Viewpoint - A class action lawsuit has been filed against SelectQuote, Inc. for allegedly violating the False Claims Act by directing Medicare beneficiaries to insurers that compensated the company the most, rather than providing unbiased comparisons of insurance plans [2][3]. Group 1: Allegations Against SelectQuote - The complaint alleges that SelectQuote failed to disclose that it directed Medicare beneficiaries to plans based on compensation rather than quality [2]. - It is claimed that SelectQuote did not provide unbiased comparison shopping for Medicare Advantage plans and received illegal kickbacks from insurers [2]. - The U.S. Department of Justice filed a complaint stating that SelectQuote received "tens of millions of dollars" in illegal kickbacks from 2016 to at least 2021 [3]. Group 2: Impact on Stock Price - Following the DOJ's allegations, SelectQuote's stock price fell by $0.61, or 19.2%, closing at $2.56 per share on May 1, 2025 [3]. Group 3: Class Action Participation - Shareholders interested in participating as lead plaintiffs in the class action must file their papers by October 10, 2025 [4]. - Shareholders can remain absent class members and still be eligible for recovery without participating in the case [4]. Group 4: Company Background - Robbins LLP is a law firm recognized for its work in shareholder rights litigation, helping shareholders recover losses and improve corporate governance since 2002 [5].

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In SelectQuote (SLQT) To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in SelectQuote between September 9, 2020 and May 1, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648. Click here to participate in the action. NEW YORK, Sept. 24, 2025 (GLOBE NEWSWIRE) -- What’s Happe ...

Core Viewpoint - A class action lawsuit has been filed against Semler Scientific, Inc. for failing to disclose a material investigation by the U.S. Department of Justice regarding potential violations of the False Claims Act [2][3]. Group 1: Allegations and Investigations - The lawsuit alleges that Semler Scientific did not disclose an investigation by the DOJ into possible violations of the False Claims Act during the class period from March 10, 2021, to April 15, 2025 [2]. - On February 28, 2025, Semler Scientific revealed it had received an initial civil investigative demand from the DOJ in July 2017, concerning the marketing of tests using photoplethysmography technology as reimbursable by Medicare [3]. - Following unsuccessful settlement discussions with the DOJ on February 11, 2025, there was a risk of a civil lawsuit being filed, which led to a stock price drop of $4.03, or 9.38%, closing at $38.89 on March 3, 2025 [3]. Group 2: Settlement and Financial Impact - On April 15, 2025, Semler Scientific reported to the SEC that it had reached a settlement agreement with the DOJ for $29.75 million, excluding attorney fees, but noted that further payments might be necessary and the risk of a DOJ lawsuit still exists [4]. - Following the announcement of the settlement, Semler Scientific's stock fell by $3.40 per share, or 9.88%, closing at $31.00 on April 16, 2025 [4]. Group 3: Class Action Participation - Shareholders interested in participating in the class action must submit their paperwork by October 28, 2025, to serve as lead plaintiff, representing other class members [5]. - Shareholders do not need to participate in the case to be eligible for recovery and can remain absent class members if they choose [5].

Core Insights - Class actions have been initiated for stockholders of Altimmune, Inc. and SelectQuote, Inc. with deadlines for lead plaintiff petitions approaching [1] Altimmune, Inc. (NASDAQ:ALT) - The class period for Altimmune is from August 10, 2023, to June 25, 2025, with a lead plaintiff deadline of October 6, 2025 [2] - On June 26, 2025, Altimmune announced disappointing results from the IMPACT Phase 2b MASH trial of Pemvidutide, failing to achieve statistical significance in the primary endpoint of fibrosis reduction due to a higher-than-expected placebo response [2] - Following the announcement, Altimmune's stock price plummeted from $7.71 to $3.61 per share, marking a decline of 53.2% in one day [3] SelectQuote, Inc. (NYSE:SLQT) - The class period for SelectQuote is from September 9, 2020, to May 1, 2025, with a lead plaintiff deadline of October 10, 2025 [3] - On May 1, 2025, the U.S. Department of Justice filed a complaint against SelectQuote, alleging the company received "tens of millions of dollars" in illegal kickbacks from health insurance companies from 2016 to 2021 [3] - The complaint claims SelectQuote misled Medicare beneficiaries by stating it offered unbiased coverage comparisons while actually directing them to plans that paid SelectQuote the most, resulting in a stock price drop of $0.61, or 19.2%, to close at $2.56 per share on the same day [3][4]

Core Viewpoint - A class action lawsuit has been filed against Semler Scientific, Inc. for failing to disclose an investigation by the U.S. Department of Justice regarding potential violations of the False Claims Act [1][2]. Allegations and Investigations - The lawsuit alleges that Semler Scientific did not disclose a material investigation by the DOJ into violations of the False Claims Act during the class period from March 10, 2021, to April 15, 2025 [2]. - On February 28, 2025, Semler Scientific revealed it had received an initial civil investigative demand from the DOJ in July 2017, investigating whether the company violated the False Claims Act by marketing certain tests as reimbursable by Medicare [3]. - Following unsuccessful settlement discussions with the DOJ on February 11, 2025, there was a risk of a civil lawsuit being filed, which led to a significant drop in the company's stock price [3]. Settlement and Financial Impact - On April 15, 2025, Semler Scientific announced it had reached a settlement agreement with the DOJ for $29.75 million, excluding attorney fees, but noted that further payments might be necessary and the risk of a lawsuit still exists [4]. - The announcement of the settlement led to a further decline in Semler Scientific's stock price, falling by $3.40 per share, or 9.88%, to close at $31.00 on April 16, 2025 [4]. Class Action Participation - Shareholders of Semler Scientific may be eligible to participate in the class action lawsuit, with a deadline to submit paperwork by October 28, 2025, to serve as lead plaintiff [5].